Immune & Anti-Aging Research High Evidence

Thymosin Alpha-1

Naturally occurring thymus-derived peptide. FDA-approved (Zadaxin) in 35+ countries. Most studied immune-modulating peptide with decades of clinical data in infectious disease and oncology.

immunethymusT-cellNK cellFDAinfectious diseasecancerCOVID

Ask AI About This Compare Compounds

Half-life

2 hours

SKUs

Evidence

High Evidence

📖 What Is This?

Thymosin Alpha-1 (TA-1) is a 28-amino-acid peptide naturally produced by the thymus gland that plays a key role in T-cell maturation and immune regulation. It is available commercially as Zadaxin (thymalfasin) and is approved in more than 30 countries for hepatitis B, hepatitis C, and as a vaccine adjuvant. It represents one of the most clinically advanced thymic peptides with a substantial body of human clinical trial evidence.

🔬 What Are Researchers Studying It For?

Hepatitis B and C Treatment

TA-1 is approved and clinically used for chronic hepatitis B and C in multiple countries. Clinical trials show improvements in seroconversion rates and viral load reduction, particularly when combined with interferon. It is considered an immune modulator that enhances the antiviral response.

Vaccine Adjuvant Research

TA-1 has been studied as an adjuvant to enhance immune responses to vaccines, particularly in elderly individuals and immunocompromised patients who may have blunted responses to standard vaccines. Research shows improved antibody titers with TA-1 co-administration.

Sepsis and Critical Illness

TA-1 has been studied in sepsis — a life-threatening immune dysregulation. Research and some clinical trials suggest it may help restore immune competence in sepsis-associated immunosuppression, with reductions in secondary infection rates observed in some studies.

Oncology Support

Clinical research has examined TA-1 alongside chemotherapy to reduce treatment-related immunosuppression. Studies show reductions in infectious complications and improvements in immune markers during cancer treatment.

📊 What Does The Research Suggest?

Approved in 35+ countries for hepatitis B and C with randomized controlled trial evidence.
Improves vaccine responses in elderly and immunocompromised patients.
Some evidence for benefit in sepsis and critical illness-associated immunosuppression.
Reduces infectious complications during cancer chemotherapy.
Well-tolerated with a long clinical track record.

⚠️ What Should You Know Before Going Deeper?

Thymosin Alpha-1 is not FDA-approved in the United States, though it has regulatory approval in many other countries. In the US it would be used off-label or under investigational status. The evidence quality varies by indication — strongest for hepatitis, more preliminary for other applications. Cost can be significant.

⚙️ How It Works In The Body

Thymosin Alpha-1 is the most biologically active peptide produced by the thymus for T-cell education. It works by activating dendritic cells — the immune system's intelligence cells that present threats to T-cells for recognition — and by directly stimulating T-cell maturation and function. It activates toll-like receptor 9 signaling, which puts the immune system in an alert state appropriate for fighting infections. Unlike immunosuppressants, which broadly reduce immune activity, TA-1 is an immune modulator — it enhances appropriate immune responses without triggering autoimmune reactions. This makes it useful in contexts where the immune system is underperforming rather than overactive.

🛡️ Research Safety Observations

Thymosin Alpha-1 has an excellent safety profile based on decades of clinical use globally. It is remarkably well-tolerated with injection site reactions being the primary adverse effect. No significant drug interactions or serious adverse events have been consistently identified across its broad clinical use. It is not FDA-approved but is widely used clinically in other countries.

📋 Research Snapshot

High Evidence

This compound has been studied in multiple large randomized controlled trials with human subjects. The evidence base is strong and consistent across independent research groups.

Published Research Ranges

1.6mg 2x weekly (approved dose in clinical use)

Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.

📄 Research Sources

Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.

Thymosin Alpha 1 and Its Role in Immunotherapy: A Review

Annals of the New York Academy of Sciences • 2010 • DOI: 10.1111/j.1749-6632.2010.05534.x

Thymosin Alpha-1

Want More Detailed Research?